Skip to main content

Scientists Develop Sensor That Tests Saliva for Breast Cancer

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 13, 2024.

By Dennis Thompson HealthDay Reporter

TUESDAY, Feb. 13, 2024 -- Mammograms are a lifesaving misery for middle-aged women, but a new tool could make getting a breast cancer screening as easy as spitting.

Literally.

A new hand-held biosensor can detect breast cancer biomarkers from a tiny sample of saliva, researchers report Feb. 13 in the Journal of Vacuum Science & Technology B.

“Our device is an excellent choice because it is portable -- about the size of your hand -- and reusable,” said lead researcher Hsaio-Hsuan Wan, a doctoral student at the University of Florida. “The testing time is under five seconds per sample, which makes it highly efficient.”

The device uses paper test strips treated with specific antibodies that respond to targeted cancer biomarkers, the researchers explained.

When a saliva sample is placed on the strip, pulses of electricity are sent to contact points on the device.

These pulses cause the biomarkers to bind to the antibodies, which alters the electrode’s output signal enough to provide readings regarding cancer risk.

By comparison, mammograms, ultrasounds and MRI scans are all costly and require big pieces of equipment and low-dose radiation exposure, Wan said.

“In many places, especially in developing countries, advanced technologies like MRI for breast cancer testing may not be readily available,” she added in a university news release.

“Our technology is more cost-effective, with the test strip costing just a few cents and the reusable circuit board priced at $5,” Wan added. “We are excited about the potential to make a significant impact in areas where people might not have had the resources for breast cancer screening tests before.”

The device can provide accurate test results with just a drop of saliva, even if the concentration of the cancer biomarker is a minuscule one-quadrillionth of a gram per milliliter.

One of the biomarkers involves human epidermal growth factor receptor 2 (HER2), a protein that drives 15% to 20% of invasive breast cancers. Another is CA 15-3, an antigen released into the bloodstream by breast cancer.

Results showed the device could distinguish between healthy breast tissue, early breast cancer and advanced breast cancer, using those two biomarkers. Researchers tested the device in 21 human saliva samples.

“The highlight for me was when I saw readings that clearly distinguished between healthy individuals and those with cancer,” Wan said. “We dedicated a lot of time and effort to perfecting the strip, board and other components. Ultimately, we’ve created a technique that has the potential to help people all around the world.”

Sources

  • Journal of Vacuum Science & Technology B, news release, Feb. 13, 2024

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted February 2024

Read this next

FDA Tells Vaccine Makers to Target New COVID Variant for Fall

FRIDAY, June 14, 2024 -- COVID vaccine makers will be advised to update their shots to target the KP.2 variant, an offshoot of the JN.1 variant that spread widely last winter, the...

Just 1 in 20 Animal Studies Yield Treatments That Make it to Humans

FRIDAY, June 14, 2024 -- Animal studies are often considered a first step in finding new drugs and treatments for human diseases, but a new review has discovered that precious few...

Swimming 'Microbots' Could Speed Meds to Lung Tumors, Early Study Suggests

FRIDAY, June 14, 2024 -- Scientists have developed microscopic robots capable of swimming through the lungs to deliver chemotherapy directly to lung cancer cells. In early...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.